For personal use only

13 March 2025

ENTITLEMENT ISSUE – OVERSUBSCRIPTION

Australian biotechnology company Skin Elements Limited (ASX:SKN) (SKN, the Company) is pleased to advise that further to the Entitlement Issue Results as advised to the ASX on 7th March 2025, the Company has received additional oversubscription applications for a further 43,333,333 New Shares and Options raising an additional $130,000 (before costs).

The Company will now proceed to issue the oversubscribed Shares & Options under its ASX LR7.1 capacity.

An Appendix 2A and cleansing statement are to follow.

This ASX announcement has been authorised for release by the Company Secretary, Stuart Usher.

ENDS

For further information please contact

Peter Malone
Executive Chairman
Skin Elements Limited
T: +61 439 430 770
E: peter@skinelementslimited.com

Media and Investor Inquiries
James Moses
Mandate Corporate
T: +61 420 991 574
E: james@manadatecorporate.com.au

About Skin Elements

Skin Elements (ASX: SKN) is an award winning Australian owned and operated ASX-listed natural biotechnology company focused on the development of its SE Formula Biotechnology. Skin Elements world leading innovative approach to research and development of plant-based and organic sourced ingredients has enabled the creation of a portfolio of all natural plant based formulations that have global applications. Its flagship formulations have delivered products that include the SuprCuvr TGA-registered, hospital-grade plant-based disinfectant, ECO-Nurture plant bio-stimulant, Soléo Organics natural and organic sunscreen, PapayaActivs natural therapeutics skincare products and the Elizabeth Jane Natural Cosmetics brand.

Further information is available via the Company website: http://skinelementslimited.com and on the Company online store: www.sknlife.com.au.